![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Evaluation of the clinical and economic value of sofosbuvir / velpatasvir (SOF / VEL) in patients with chronic hepatitis C in Spain during the last 5 years
|
|
|
EASL 2022 June 22-26 London
Rafael Esteban1, Raquel Domínguez-Hernández2, Helena Cantero3, Miguel Ángel Casado2
Hospital Vall' d'Hebrón, Barcelona, España; 2Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, España; 3Gilead Sciences, España
![0714221](../images/071422/071422-11/0714221.gif)
![0714222](../images/071422/071422-11/0714222.gif)
![0714223](../images/071422/071422-11/0714223.gif)
![0714224](../images/071422/071422-11/0714224.gif)
![0714225](../images/071422/071422-11/0714225.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|